Yahoo Italia Ricerca nel Web

Risultati di ricerca

1. finance.yahoo.com › news › candel-therapeutics-nasdaq-cadlCandel Therapeutics (NASDAQ: CADL) Reports Positive Data From...

   finance.yahoo.com › news › candel-therapeutics-nasdaq-cadl

   • Cache

   15 ore fa · Long-term survival data in PDAC was recently updated with eight months of further follow-up since the first analysis was presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting.

2. www.prnewswire.co.uk › news-releases › biotech-advances-inBiotech Advances in 2024: Innovative Treatments Aim to Boost...

   www.prnewswire.co.uk › news-releases › biotech-advances-in

   • Cache

   2 ore fa · For 8 out of 16 patients with resected PDAC, BioNTech's mRNA vaccine, autogene cevumeran, demonstrated persistence of T cells, which is associated with a longer median recurrence-free survival in ...

3. markets.ft.com › data › announceCompany Announcements - Financial Times

   markets.ft.com › data › announce

   • Cache

   15 ore fa · Should the combination of pelareorep and mFOLFIRINOX produce a similarly positive outcome, an even broader range of metastatic PDAC patients may benefit from pelareorep-based therapy." The cohort is supported by a US$5 million Therapeutic Accelerator Award grant from the Pancreatic Cancer Action Network (PanCAN).

4. markets.financialcontent.com › stocks › articleCandel Therapeutics (NASDAQ: CADL) Reports Positive Data From...

   markets.financialcontent.com › stocks › article

   • Cache

   3 ore fa · The randomized, controlled clinical trial is specifically looking into the safety and efficacy of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection – if possible – in borderline resectable pancreatic ductal adenocarcinoma (PDAC).

5. pipelinereview.com › innovent-delivers-oral-presentations-atInnovent Delivers Oral Presentations at the 2024 ASCO Annual...

   pipelinereview.com › innovent-delivers-oral-presentations-at

   • Cache

   15 ore fa · In the presented clinical data, IBI389 has shown promising efficacy in advanced G/GEJ tumors and PDAC, including those subjects with low and moderate CLDN18.2 expression. Notably, IBI389 is the world’s first bispecific antibody targeting CLDN18.2/CD3 to show encouraging efficacy signal in PDAC, representing a breakthrough for innovative treatments in difficult-to-treat cancers.

6. www.advfn.com › stock-market › stock-newsNeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced ... -...

   www.advfn.com › stock-market › stock-news

   • Cache

   15 ore fa · A Phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat MSS-CRC and PDAC gastrointestinal tumors 2563 ...

7. www.prnewswire.com › apac › news-releasesInnovent Delivers Oral Presentations at the 2024 ASCO Annual...

   www.prnewswire.com › apac › news-releases

   • Cache

   6 minuti fa · In the presented clinical data, IBI389 has shown promising efficacy in advanced G/GEJ tumors and PDAC, including those subjects with low and moderate CLDN18.2 expression.